Adil Duru
Director, Business Development Glycostem Therapeutics
Adil’s main research and development interest is exploring novel NK cell and T cell based cancer immunotherapy approaches including genetically engineered NK cells and T cells. He has extensive experience in introducing T cell receptors, chimeric antigen receptors and pattern recognition receptors to NK cells and T cells.
Seminars
Wednesday 25th February 2026
Panel Discussion: Feasibility & Merits of Setting up Point of Care Manufacturing to Drive Patient Access & Reduce CGT Costs
2:15 pm
- Evaluating the true feasibility and practicality of point-of-care manufacturing in today’s CGT landscape
- Weigh upfront costs, staffing, and infrastructure requirements against potential long-term savings
- Discussing whether the benefits of local access outweigh regulatory, operational, and scalability hurdles
Wednesday 25th February 2026
Advancing Second-Generation Off-the-Shelf CAR-NK Therapies for Safer, More Scalable Cancer Treatment
11:15 am
- Explore how CAR-engineered NK cells enhance tumour targeting, persistence, and safety
- Discuss how these next-generation, allogeneic NK products improve manufacturability, cost efficiency, and clinical accessibility
New Data
